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ABSTRACT 
The common theme and aim for this thesis was to explore the epidemiology and the 
diagnostic possibilities of patients with non-malarial febrile infections of tropical origin, with 
both the individual patient perspective and the more general public health aspects in focus. 
Analysis from two study areas, Sweden and Mozambique, are presented in the project. 
The infectious disease panorama in Mozambique has to a large extent been a blind spot. 
Further epidemiological studies, aiming at more knowledge to guide decisions on preventive 
measures, are needed. We performed two prospective investigations. The first one was a pilot 
sero-epidemiological study on vector-borne viral zoonoses, in which we screened serum 
samples from patients attending a health care clinic in the suburb of the capital Maputo. In the 
analysis we found that 29% of the patients screened had an antibody response against one or 
more of the viral pathogens. Our conclusion, based on these results, was that exposure to 
chikungunya virus (CHIKV), dengue virus (DENV) and Rift Valley fever virus (RVFV) had 
taken place, and that these viruses are circulating in the country. The second study was an 
investigation of the DENV outbreak in the cities Pemba and Nampula. We analysed serum 
samples for DENV by PCR from patients seeking medical attention for fever during 2015-
2016. The results including PCR positive samples, serotyping and sequencing of strains, 
confirmed that DENV serotype 2 is now endemic in northern Mozambique. 
In the Swedish multicentre study we prospectively included febrile travellers returning to 
Sweden from tropical areas defined as malaria endemic. Epidemiological data from 
questionnaires and clinical diagnoses given to patients by their attending doctors were first 
compared with results from a panel of extended laboratory diagnostics, primarily on 
convalescent samples. We then focused on the possibilities for early diagnostics with PCR, 
particularly for cases where no relationship between the febrile illness and a microbial 
pathogen had been identified. We also developed a universal PCR for diagnosis of early 
phase DENV infection. This universal single probe real time RT-PCR for DENV was then 
used for the DENV analysis on acute samples. The results showed that infectious disease 
clinicians in Sweden, when taking care of febrile travellers returning from the tropics, were in 
general able to establish a diagnosis based on laboratory diagnostics for relevant pathogens. 
That being said, we also noted that 30 % of the patients included in the study were dismissed 
with the diagnosis fever of unknown origin. It was also apparent from the results that 
influenza virus infection was a frequent, and often missed, diagnose among febrile travellers, 
regardless of the time of year. The antibody screening also identified several additional cases 
of dengue infection. When including the PCR for DENV in the diagnostic kit, it was possible 
to reduce even further the number of cases with diagnosis of unknown fever. This confirms 
that the universal PCR for DENV is a sensitive, specific and valuable diagnostic tool to use 
during the first 5 days in the acute phase of illness. Apart from influenza and DENV, 
Rickettsia and Leptospira infections stood out as differential diagnoses that needed to be 
addressed. 
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LIST OF ABBREVIATIONS 
Arbovirus Arthropod-borne virus 
BSL Biosafety level 
CDC Centers for Disease Prevention and Control 
CHIKV Chikungunya virus 
cDNA Complementary DNA 
DENV Dengue virus 
DENV 1-4 Dengue virus serotyp 1-4 
DNA Deoxyribonucleic acid 
ECDC European Centre for Disease Prevention and Control 
ELISA Enzyme-linked immuno sorbent assay 
IFA Immunofluorescence assay 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
JEV Japanese encephalitis virus 
MAT Microscopic agglutination test 
MicroIF Indirect mikro immunofluorescence 
NS1 Non-structural protein 1 
PCR Polymerase chain reaction 
RNA Ribonucleic acid 
RT-PCR Reverse transcriptase PCR 
RVFV Rift Valley fever virus 
SMI Swedish Institute for Infectious Disease Control, now 
integrated in the Public Health Agency of Sweden 
VFR Visiting friends or relatives 
WNV West Nile virus 
ZIKV Zika virus 
 
  
  
DEFINITIONS 
Antibody titer Measurement of how much antibody has been produced, the 
dilution of the sample (in a serial dilution) still giving a 
positive result 
Antigen A foreign substance or a microbe that when entering the body 
stimulates an immune response 
Communicable 
disease 
A disease that can be transmitted from for instance person to 
person, or from animals to humans 
Endemic Natural to or characteristic of a specific place or people 
Epidemiology Study of diseases in populations 
Homologous Derived from or developed in response to organisms of the 
same species 
Incidence The occurrence of new cases of a particular disease in a 
population within a specified period of time 
Outbreak Increased number of cases of an infectious disease in a certain 
geographical area during a period of time. A sudden rise in 
the incidence of a disease 
Phylogenetic clade Evolutionary relationships. A clade is a group of organisms 
with a common ancestor and all its lineal descendants 
Prevalence The percentage of a population that is affected with a 
particular disease at a given time 
Vector An insect or other organism that transmits a pathogen  
Zoonotic disease A disease that can be transmitted between animals and 
humans 
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1 AIMS AND OBJECTIVES 
The aims of the thesis were to explore the epidemiology and the diagnostic possibilities of 
patients with non-malarial fever of tropical origin, with both the individual patient 
perspective and the more general public health aspects in focus. The specific objectives were 
as follows:  
1. Analyse and describe the spectrum of infectious diseases brought to Sweden 
from the tropics with febrile returned travellers.  
2. To perform an extended analysis of blood samples from clinical cases in 
Sweden with unknown or unspecified infectious aetiology after travel. 
3. Analyse the seroepidemiology against zoonotic viral infections in residents of 
Mozambique. 
4. Contribute to the methodological development of laboratory procedures for 
early detection of pathogens in endemic countries as well as among returning 
travellers. 
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2 INTRODUCTION 
2.1 BACKGROUND 
International travelling of today is intense, providing a channel for communications and 
positive interactions for people all over the world. On the other hand, travelling also provides 
a channel for human infections to spread rapidly all over the globe (1-3). Furthermore, apart 
from international travel, also other factors such as climate changes, international trade and 
exchange of goods (4), are ways by which infections could expand their geographical area of 
endemicity. Particularly when vectors such as mosquitos play a role in the spread of the 
infection, vectors being organisms transmitting a pathogen. The current challenge for 
communicable disease prevention and control is to find a way to minimize these risks and to 
protect the population against the spread of communicable diseases. And to do it without 
undermining the sustainability and prospects of increased world-wide interactions. In this 
respect, it is essential to consider the effects of control measures, not only on travellers, but 
also on those living in endemic countries.  
The infectious disease panorama in tropical countries is vast. In tropical areas, and when 
defined as malaria endemic parts of the world, malaria remains important. But the fact is that 
a wide number of patients seeking medical attention for fever in the tropics are negative when 
tested for malaria (5). In spite of this, further diagnostic investigations are not always done, 
leading to frequent cases of unclear diagnosis (6). Investigating these alternative diagnoses, 
particularly looking at patients with fever of unknown origin, is one of the objectives of this 
thesis.  
2.2 MICROBES AND DIAGNOSTICS 
The diagnostic challenges of fevers with tropical origin are many. They include the broad 
spectrum and similarity of clinical presentations of diseases such as malaria, dengue, 
chikungunya, leptospirosis and rickettsial infections. Also gastrointestinal infections, 
respiratory tract infections and septicaemia, can be difficult to distinguish from the more 
tropical associated diseases.  
This thesis will focus on non-malarial causes of fever with tropical origin. Malaria is still a 
primary suspicion in fevers of tropical origin, causing a significant burden of disease. But its 
numbers have been diminishing over the last years. For example in regard to childhood 
mortality, a systematic review found that mortality for malaria under 5 years of age was 
reduced by more than 30% between 2000 and 2015 (7). According to the 2016 WHO report 
the number of malaria endemic countries has gone from 108 in year 2000 to 91 countries, 
with a reduction in incidence rate by 41% globally during the same period (8). Despite this 
remarkable progress, in large areas of the tropics, malaria still is a prime diagnosis to suspect 
and rule out in febrile patient. 
In many tropical countries HIV infection and tuberculosis are also infectious diseases with a 
large public health burden. These diseases also need to be mentioned in this context, but will 
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not be explored further in this thesis. It should be noted that primary HIV infection is one of 
the differential diagnosis in the febrile patient, travellers and residents alike (9, 10). 
Additionally HIV infection in the advanced stage with an immunocompromised patient can 
predispose for other infections, such as tuberculosis (11). 
When malaria has been excluded in the febrile patient, the differential diagnosis of non-
malarial febrile diseases will have to be explored. Some authors even state that patients with a 
positive malaria finding should be further investigated for co-infections such as those caused 
by arbovirus (6). 
Which pathogens to consider might vary, depending on information about clinical symptoms, 
and destination of travel or the tropical country of residence (12). In view of the 
symptomatology rarely being disease-specific, a more extended analysis might be needed. 
Apart from which disease to suspect and test for, another challenge is to have access to 
appropriate tools, allowing for correct diagnoses both in patients residing in endemic 
countries and in travellers returning home with fever after visiting such regions. Timing and 
type of samples available for diagnostics have to be considered when choosing the diagnostic 
methods, both in relation to the time of exposure and for how long a period the patient has 
been symptomatic (13). Furthermore, early diagnosis might be important in order to pinpoint 
diseases needing medical treatment and to prevent the severe clinical complications 
associated with a number of infections.  
Thus the questions are:  
Which pathogen(s) could be responsible for the febrile illness?  
When investigating the cause of fever, can the pathogen still be found at the time the samples 
are collected or do we have to rely on indirect evidence from the patient´s immune response 
to the infection?  
 
 
 
 
 
 
 
Figure 1. Clinical phases and schematic illustration of diagnostic possibilities with PCR and 
antibodies against the pathogen (IgM and IgG) over time. The figure is schematic, but could 
for instance illustrate the relationship over time between different diagnostic methods for 
arbovirus infection.  
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With arbovirus as an example, figure 1 shows that in the early phase of infection, even 
shortly before the patients have any symptoms, viral particles become present in the 
bloodstream. In the early stage, the pathogen can be diagnosed with PCR. A few days later, 
when IgM is being produced, testing for IgM antibodies against the pathogen becomes a 
diagnostic possibility. When more than 5 days have passed since the patient presented with 
symptoms, it is less likely to get a positive PCR result. Diagnostics after the acute phase will 
thus have to rely on the antibody response. In the later symptomatic phase and in the early 
convalescent phase the IgG antibodies against the pathogen will increase. The diagnostic 
method at this stage will then be comparing the IgG titer from the early symptomatic phase 
with the IgG level in the convalescent phase. 
2.2.1 Detection of the pathogen 
Direct detection of the microbe, or parts of the microbe, can be made from culturing the 
organism, microscopy, from molecular methods such as PCR, and by rapid tests for antigen 
detection. With direct detection you are actually able to see or identify the pathogen itself. 
These types of diagnostics are usually feasible in the early phase of an acute infection, just 
before symptoms have started or a few days after. The symptoms of the patient being an 
indirect indicator of the multiplication of the pathogen and the body´s response against the 
intruder. However in chronic infections the symptoms can be low-grade and the pathogen can 
be found for a prolonged period of time. 
Culture  
Culture can be performed on both viral and bacterial samples. Culture conditions and the 
possibility for a positive culture vary with the specific organism and the material collected. 
Some viruses and bacteria are more difficult to culture, and certain organism are classified as 
hazardous and have to be handled within a high-containment laboratory, i.e. a BSL-3 or BSL-
4 facility. 
Microscopy  
Microscopy can be performed if you have a high enough concentration of organism. Electron 
microscopy (high resolution) is needed for visualizing virus-particles. Several species of 
bacteria can be seen in light microscopy after staining. Both clinical information and the use 
of additional methods might be needed for an accurate diagnosis. 
Molecular methods 
PCR (polymerase chain reaction) and NGS (next-generation sequencing) are molecular 
methods, analysing DNA or RNA, identifying organisms based on its nucleotide order.  
Real time PCR 
The PCR amplifies DNA. When preparing RNA it will therefore have to be transcribed by 
reverse transcriptase into complementary DNA (cDNA). The method measures the 
amplification of DNA after each cycle, using fluorescent dyes. In the one step real time PCR 
the reverse transcription is included, and the cDNA product is then amplified. The real time 
PCR amplifies distinct parts of the genome strand, defined by the sequences of the primers. It 
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is important that these are as specific and as unique as possible for the organism you are 
trying to find. The real time PCR is a qualitative method. If your aim is to measure the 
product, it needs a standard to be included to become quantitative. 
The method is specific, positive results giving a diagnosis of high accuracy. With the new 
robotic extraction systems and thermal cyclers the analysis is fast, avoiding delays in 
diagnosis. The method has a low limit of detection, meaning that even a low amount of the 
pathogen can be detected. However the target regions for the primers and probes need to be 
sufficiently preserved. Genetic variations and new strains can develop. The specificities of the 
primers for the target RNA/ DNA need to be up-to-date and frequently checked against the 
genome sequences for new and different strains of the pathogen of interest included in a large 
genetic sequence database, e.g. GenBank, and necessary adjustments of the primer sequences 
made. The detection limits of the PCR should be known. 
Next Generation Sequencing (NGS)          
The method can sequence for instance whole virus genome. The first step of the NGS is a 
random fragmentation of RNA and/or DNA in the sample. Then the so called sequencing 
library is prepared, followed by amplification and sequencing. The data collected is then 
analysed in a computer and the results are interpreted (14, 15). 
2.2.2 Detection of antibodies 
Serology studies the immune response of the patient against the microbe, analysing blood 
serum for antibodies against the specific antigen. Detection of antibodies against the pathogen 
is an indirect method, not directly visualizing the pathogen itself. Furthermore, the antibodies 
can be the result of vaccination against the disease, and a single titer can then not differentiate 
between infection and vaccination. Despite this the methods can be specific, particularly 
when comparing titers in paired samples, the first sample taken during the early phase of the 
infection and the second sample during the convalescent phase.  
Analysing immune response is a well-established method in the field of infectious diseases, 
using serological diagnostics of IgM and IgG titers. For interpretation of the results clinical 
information is needed, as the resulting titers are depending on when the samples were taken 
in relation to time of onset of disease. The antibodies are directed against the pathogen. The 
specificity of the response will depend on the type of antibody (IgM or IgG), the rise in titer 
(IgG), and the pathogen (cross-reactivity). In the acute phase of the infection, after a first time 
exposure to the pathogen, the IgM antibody is the earliest antibody to be found. It can be 
detected shortly after the symptoms have started, the titer rising over a couple of weeks, and 
then it vanes off. If IgM antibodies are found directed against a specific pathogen it clearly 
indicates the cause of infection. IgG titers take longer time before they are detectable in a first 
time infection with the specific pathogen. Once the IgG titers have risen, they usually stay on 
a high level for a longer period of time. If the patient is once more exposed to the pathogen, 
the level of IgG antibodies can rise rapidly. An acute, first time, infection can be verified by 
seroconversion or a four-fold or more increase in IgG titer, comparing antibody titers in two 
serum sample- one acute sample early on when the patient is presenting with symptoms, and 
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a second so called convalescent sample, preferably taken at least one month after the first 
sample. Studying the antibody response means that diagnosis can be made also when the 
acute stage of pathogen replication has passed, studying the immune response to the 
exposure. Cross-reactivity can be a problem, and is for instance common between flavi-
viruses (16, 17). It is thus important to now the vaccination status against for instance yellow 
fever and tick borne encephalitis. Non-specific reactions can occur in sero-diagnosis, and are 
important to consider when interpreting a positive result.  
Some of the serological methods used for antibody detection are briefly presented below. 
ELISA (Enzyme-linked immuno sorbent assay)  
Several varieties of the ELISA assay exist. In the studies presented in this thesis we have used 
indirect ELISA assays in order to assess if there is an immune response (antibodies) in the 
patient sample against the pathogen. In this method, the wells in a micro titer plate are coated 
with antigen from the pathogen. The patient sample is added to the microtiter plate. After 
washing, a second labelled antibody against the presumed complex is added, as well as an 
enzyme substrate allowing for colour to develop if antibodies from the patient sample have 
bound to the pathogen. The colour reaction is then evaluated and read in a photometer plate 
reader.  
Immunofluorescence assay (IFA)  
Several different IFA methods are available, but here we present the method used for the 
studies and at the Public Health Agency of Sweden. Cultured cells are initially infected with 
the pathogen. The cells are then grown on 12-well slides to a confluent layer. Patient serum is 
serial diluted and added. After washing steps, fluorescein marked goat anti human IgG is 
subsequently added. The reaction is evaluated and the extent of cells with cytoplasmic 
fluorescence is estimated using a fluorescence microscope (18). 
Agglutination  
The agglutination methods are based on the fact that, when patient serum and bacterial 
antigen are added in a suspension, a clumping reaction will occur if antibodies against that 
specific, homologous, pathogen are present in the patient serum. Agglutination is used in the 
MAT test for leptospirosis (see below). 
Neutralization tests are used in viral diagnostics. A neutralization test can be performed in 
several different ways, studying either the immune response or the presence of viral 
pathogens in a sample. An example of the method is the so called Plaque test (Plaque 
reduction neutralization test) where the presence of antiserum neutralizes the virus from 
infecting the cultured cells used in the test. 
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2.3 EMERGING ARBOVIRUSES 
Vector borne diseases belonging to the group arthropod-borne viruses (arboviruses), are a 
group of viruses that have the potential to increase their geographical distribution and affect 
previously virgin human populations (19, 20). The arboviruses that are pathogenic to humans 
are all single-stranded RNA viruses. The clinically most important arboviruses belong to one 
of the four families Bunyaviridae, Flaviviridae, Reoviridae and Togaviridae, see examples in 
table below. The incubation period is usually short (3-10 days). The clinical picture range 
from a mild and self-limited febrile illness, maybe with a rash, to severe joint and muscle 
pain, haemorrhagic disease and encephalitis. It is often difficult to distinguish the different 
arboviral diseases merely based on symptomatology (21-23). 
  
Table 1. Clinically relevant arbovirus of tropical origin  
 CHIKV DENV RVFV WNV ZIKV 
Family 
Genus 
Togaviridae 
Alphavirus 
Flaviviridae 
Flavivirus 
Bunyaviridae 
Phlebovirus 
Flaviviridae 
Flavivirus 
Flaviviridae 
Flavivirus 
Most common 
vector 
Ae. aegypti 
Ae. albopictus 
Ae. aegypti 
Ae. albopictus 
Aedes spp.  
Culex spp. and 
other 
Culex spp. 
Ae. atropalpus 
Aedes spp. 
Ae. aegypti 
(Ae. albopictus) 
Geographical 
distribution 
Tropics- 
subtropics 
Tropics- 
subtropics 
Sub-Saharan 
Africa 
Worldwide Tropics -
subtropics 
Clinical 
symptoms 
Fever, severe 
arthralgia, 
myalgia, rash 
Fever, 
headache, 
arthralgia, 
myalgia, 
vomiting, rash. 
Haemorrhagic in 
severe cases 
Fever, liver 
abnormalities, 
encephalitis, 
haemorrhagic 
fever 
Fever, 
headache, 
body aches, 
nausea, 
vomiting. 
Encephalitis in 
severe cases 
Fever, rash 
Neurological 
complications 
Congenital 
malformations 
 
Different factors such as environmental change, travel or transport of goods, can facilitate the 
vectors expanding to new regions, providing the conditions necessary for these viruses to 
spread and increasing their risk of becoming a threat for public health. Arboviruses are often 
present in overlapping endemic regions coinciding with malaria, causing outbreaks of varying 
size and infections with similar symptomatology, challenging the diagnostic skills and 
possibilities (23, 24).  
2.3.1 Chikungunya virus 
Chikungunya virus (CHIKV) is an alphavirus. Sudden onset of fever and severe joint pain are 
clinical symptoms characteristic for CHIKV infection (25). It is a vector borne disease, 
transmitted by day-biting Aedes mosquitoes (26), particularly in tropical areas of Africa, Asia 
and the Indian subcontinent. It was first isolated in eastern Africa (Tanzania) in 1953 during 
an outbreak (20). Episodic outbreaks have occurred in Africa, India, and Southeast Asia, 
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spreading to Indonesia by the 1980s. In recent years it has spread to many subtropical 
countries, having been identified in 60 countries (25). During the last 10 years it has rapidly 
spread from what started as an outbreak in Kenya to the islands of the Indian Ocean and then 
also to the Americas. Following the wake of the large outbreak of chikungunya fever on 
islands in the Indian Ocean in 2006 (26-28), the fever was introduced in Italy by a returning 
traveller (29). There, it spread to local mosquitoes, the Aedes albopictus mosquito being 
already established in Southern Europe (30, 31). Later, in August 2007 a chikungunya 
outbreak was formally declared in Italy, for the first time in Europe (32). Being a virus that 
also can be transmitted by blood transfusion from an infected donor, these outbreaks pose a 
serious challenge to the health care system and to sustain blood supply (33). 
Chikungunya virus now circulates in the same endemic areas as dengue virus and malaria, 
and the symptomatology for these diseases can be undistinguishable (20). 
2.3.2 Dengue virus  
Dengue virus (DENV) is a flavivirus with four related, but antigenically distinct serotypes. 
Infection with one of the serotypes 1-4 only confers immunity only to that specific serotype. 
Infection can present with a varying degree of symptoms (34), and differences in clinical 
symptomatology have in some settings been noted between serotypes (35, 36). Many persons 
with DENV infections have a mild, unspecific febrile illness, or may even be asymptomatic, 
and the disease resolves without complications. However in some cases severe disease 
develop, with bleeding, organ failure and shock, thus requiring urgent correct diagnosis and 
treatment (37). Severe disease outcome has been related to a second infections of DENV with 
another, heterologous, serotype (38, 39). 
For most of the DENVs that cause human infection, humans are the only vertebrate host 
(both reservoir and amplification host) (20, 40). DENV is the most widespread arbovirus 
affecting humans and all four serotypes are now found in Asia, Africa, and the Americas (41-
43). In the 1970s only nine countries were considered endemic for DENV. Now largely 
distributed in the tropical and subtropical regions of the world, currently there are more than 
100 countries in Southeast Asia, Latin America, and the Western Pacific region affected by 
DENV. According to recent WHO estimates approximately 96 million persons present with 
symptoms of DENV infection out of the probably 390 million people that become infected 
with DENV per year. Ten times as many, 3.9 billion people, that are living in 128 different 
countries are according to WHO at risk of DENV infection (44). Several of the endemic 
countries are tourist destinations and visited by many travellers.  
The vectors are the daytime biting mosquito Aedes aegyptii together with Aedes albopictus 
(30). The mosquitoes being present pose a risk for autochthonous transmission of DENV, that 
could when imported cause local transmission in southern Europe (45, 46), the vector Aedes 
albopictus being well-established on several locations (31). Local transmission of DENV has 
occurred in Europe. In 2012-2013 there was an outbreak of DENV-1 in the island of Madeira, 
with more than 1000 confirmed cases. Aedes aegypti , one of the vectors for DENV, is known 
to be present in Madeira since 2005 (47). 
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2.3.3 Rift Valley Fever virus 
Rift Valley Fever virus (RVFV) is a phlebovirus belonging to the family Bunyaviridae. It is a 
viral zoonosis, first recognized 1912 in the Rift Valley in Kenya (48). Since then there have 
been several epizootic outbreaks mainly affecting livestock in Africa and the Arabian 
Peninsula, with the potential for worldwide spread. The epidemiology of RVF is complex, 
and from being a mild disease rarely affecting humans during the 20th century outbreaks, the 
number of human cases and the severity, including risk for mortality, have clearly increased 
(49). RVFV has been classified as a bioterrorism agent by the World Organization for 
Animal Health (OIE) (49, 50). RVFV is mainly transmitted by mosquitos of the Aedes and 
Culex species, but several different mosquitoes, flies and ticks can be vectors (49-52). Direct 
transmission from infective body fluids is also possible. In livestock it has been associated 
with congenital abnormalities and fetal death (49, 51). An increased risk of miscarriage has 
been reported in humans, studying RVFV infected mothers (53). In light of the ongoing 
ZIKV outbreak this raises concern for the effect it could have on pregnant mothers and their 
unborn child (49), especially if RVFV continuous to expand into new geographical areas. 
2.3.4 West Nile virus 
West Nile virus (WNV) is a flavivirus and one of the most widespread arboviruses, with 
several outbreaks involving humans and/or horses in Europe and in North America (16). It 
was not introduced into the USA until 1999, but then it spread rapidly (54-56). Birds play a 
key role in the cycle of the virus together with species of Culex mosquito being the main 
vector (57). Humans and other mammals are dead-end hosts (58). Infected humans are mostly 
asymptomatic (80%), but there is risk of neurological symptoms in less than 1% of the cases 
(West Nile neuroinvasive disease). WNV transmission has been known in Europe at least 
since the 1960s when it emerged in the Camargue in the south of France. Transmission 
occurs from time to time in Central European and Mediterranean countries (59). A public 
health implication is the risk of human to human transmission from blood transfusion of 
infected donors. During the 2010-2012 outbreak in North-eastern Italy, blood-donors in the 
affected provinces were screened through nucleic acid test (NAT) (16, 60). 43% of the 
reported WNV RNA-positive blood donors were asymptomatic (16).  
2.3.5 Zika virus 
Zika virus (ZIKV) is, similar to DENV and CHIKV, primarily transmitted by day-biting 
Aedes mosquitos. It is a flavivirus that was first isolated from a rhesus monkey in the Zika 
Forest of Uganda in 1947 (61). The virus was not found outside Africa and Asia until 2007. 
Then it was detected in an outbreak on a Micronesian island (61), the symptoms were 
described as mild and self-limited.  
The ZIKV outbreak in Latin America is a recent example of the public health impact caused 
by an emerging arbovirus. When reaching a former unexposed large population in South 
America, it has had massive public health impact, particularly for women in childbearing age 
and especially in Brazil. Many questions on risk factors still remain to be answered (62).  
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The outbreak was a challenge for the health organisations, particularly in locations where the 
outbreak was new and ongoing. With the intense focus of attention on ZIKV infection the 
risk of other diseases being missed or misdiagnosed was apparent, causing an added health 
threat. In light of the ZIKV outbreak an increased number of cases of falciparum malaria in 
Venezuela and Colombia was reported (63). The same trend is believed to have occurred in 
other countries of the region as described in ProMED mail 27 Aug 2016 (64).  
2.3.6 Mayaro virus  
Mayaro virus (MAYV) is an alphavirus closely related to CHIKV (65), and was first isolated 
in Trinidad 1954. MAYV is endemic in South America (65), and causes a dengue like illness 
(20, 66). As for CHIKV the presence of arthritis might be a distinguishing symptom of 
alphavirus from other differential diagnoses (65). A case report in Europe has recently been 
published on a French citizen with a dengue-like syndrome and arthralgia after a travel in 
French Guiana (67). This was the 6th case of confirmed MAYV infection reported from 
Europe, but under-diagnosis among travellers is very likely, and the real incidence among 
travellers is not known. Even though mosquitoes of the Culicidae family are the primary 
vector there is concern that MAYV also could be transmitted by Ae. albopictus which already 
is established and expanding in Europe (67). This calls for increased awareness and attention 
on possible MAYV infections, leading to a correct diagnosis and timely preventive measures 
aiming at limiting spread of both the vector and the infection. 
2.3.7 O’nyong-nyong virus  
The o’nyong-nyong virus (ONNV) is an alphavirus, and the symptomatology is similar to 
CHIKV infection. ONVV seems to be restricted to Africa, with reported outbreaks in East 
Africa, but also reports from western Africa with cases from for instance Chad and Nigeria 
(65, 68, 69). There are single reports on cases in travellers returning to Europe, for instance 
from Chad or Kenya to Europe (68, 70). Humans might be the only vertebrate host. The virus 
is primarily spread by anopheline mosquitoes (71, 72). 
2.3.8 Diagnostics of arbovirus 
The symptomatology after arbovirus exposure is often unspecific, with several differential 
diagnosis to consider and causing a diagnostic challenge. The laboratory methods primarily 
used are antibodies against the pathogen and PCR. 
PCR  
In early acute stage of the disease, when we can assume that the febrile patient is viremic 
(73), molecular methods such as RT-PCR is a good choice for arbovirus detection (65). In 
acute dengue the duration of dengue viremia (73) has been shown to range from 2-12 days, 
but most patients had detectable circulating virus for 4-5 days. Sensitivity and specificity of 
the tests have to be considered, and for DENV diagnostics several specific and sensitive 
PCR-based assays have been developed including a DENV serotype-specific multiplex real-
time RT-PCR approved by the US Food and Drug Administration (74). However most of 
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these assays need a large number of primers and/or probes to be able to detect all four DENV 
serotypes, complicating modifications when new genetic variants of DENV appear. 
Additionally, simultaneous circulation of new and old strains has been reported (75) and also 
spillover of sylvatic DENV to humans (76) requiring a wide range of strains to be covered for 
detection.  
Also for the other arboviruses described above diagnostics with PCR technique is available. 
Serotyping with PCR 
PCR-based techniques can be used for determining the infecting DENV serotype during the 
early, 5-6 days, of DENV disease. Both multiplex and singleplex methods exist. Singleplex, 
serospecific real time PCR has the advantage that they can easily be modified if new variants 
of the DENV strains emerge (77). Sequencing can also be done to verify the specific 
serotype. 
Nonstructural protein 1 
Diagnostics of DENV can be made by detection of non-structural protein 1 (NS1), an early 
soluble viral antigen secreted by DENV infected cells (78, 79). As for viral RNA, NS1 can be 
found from the onset of disease (80). The NS1 Viral antigen peak is around day 3 post onset 
of fever. The NS1 protein may be detectable in serum for some days longer than the viral 
nucleic acid, which usually is present until at least day 5 (81-83). An NS1 ELISA was 
introduced in 2006, but the most used NS1 antigen test today is one of the commercially 
available rapid tests. However, the sensitivity of the rapid tests is low compared to the high 
sensitivity of the PCR (81). In secondary DENV infection NS1 is present during a shorter 
period of time, cross-reacting antibodies forming immune complexes (80). Furthermore, the 
NS1 tests have a lower sensitivity in secondary DENV infection compared to in primary 
DENV infection (81). 
Serology 
When it comes to serology of flavivirus there are some things to keep in mind. Cross-
reactions in flavivirus serology are well-known and can occur either after previous flavivirus 
infections or after vaccination with for instance Yellow Fever vaccine. Thus it is important 
that the clinician reports the vaccination status of the patient when referring a sample for 
antibody analysis. 
For DENV it is also essential to know if the patient has a primary or secondary infection with 
DENV, since the immune response will differ for the two. A primary infection of DENV is 
characterized by a slow and low-titer antibody responses. In general IgM and IgG antibodies 
will start to appear during the early post-febrile period (84), where the IgM response is 
dominating and can become present day 2 to 5 after onset of fever (80, 85, 86). IgG 
antibodies generally become detectable at the end of the first week of illness (41). In 
secondary infections IgG antibody titers rise rapidly while IgM antibody levels can remain 
low or undetectable (85).  
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Laboratory confirmed diagnosis  
A confirmed DENV case can be defined as having either a fourfold or more increase in 
paired samples of IgG antibody titer between the acute and the convalescent paired sample 
(24), a positive PCR finding for DENV, or the combination of a positive NS1 antigen and 
DENV IgM in the acute sera. 
Similarly for other microbial pathogens a more than fourfold increase in IgG titers or a 
positive PCR result confirms the diagnosis, as does a positive culture or virus isolation. 
Today, PCR is the best way to diagnose patients with suspected arbovirus infection (65), but 
maybe the future lies in new “screening” diagnostic methods for unknown febrile illnesses, 
such as the further development of the next generation sequencing (87), and broader but 
specific immunological methods for the later stage of viral diseases that is after the viremic 
phase. 
  
Figure 2. Positive indirect IFA for DENV.  Kindly provided by Sirkka Vene 
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2.4 OTHER TROPICAL VIRAL AND BACTERIAL PATHOGENS 
A large number of viral and bacterial pathogens can of course cause infections of tropical 
origin, many of them also being common in other parts of the world. One such disease is HIV 
infection. Within this thesis only a limited number of pathogens have been further 
investigated, mainly to explore the possibility of them being neglected diseases in the 
diagnostic process.  
2.4.1 Hantavirus 
Hantaviruses are found worldwide and are important zoonotic pathogens. Two forms of 
hantavirus disease are seen in different parts of the world. In Asia and Europe haemorrhagic 
fever with renal syndrome or nephropathia epidemica can be seen, while in the Americas 
hantavirus infection is associated with a cardiopulmonary syndrome. Outdoor activities and 
inhalation of dust contaminated with rodent urine or other excretes, can be a risk of exposure 
(88). Over 50 species of hantaviruses have been identified worldwide, however up until 2006 
none had been reported from Africa (89). Serology is still the golden standard for Hantavirus 
diagnostics. The primary differential diagnoses are leptospirosis (renal failure) and 
rickettsiosis (rash, and maybe pulmonary oedema, but the eschar distinguishes from 
hantavirus infection) (90). 
2.4.2 Influenza virus 
Influenza virus is a respiratory virus. The infection is a highly transmissible disease from one 
person to a non-immune individual. Due to the antigen shift and drift of the virus, immunity 
after infection is seldom protective. A virus strain that has changed enough in its antigen 
properties will have the chance to infect and spread. Influenza appears in cycles. The 
seasonality differs over the globe. In the northern hemisphere the yearly season for influenza 
typically peaks during the winter months (December-February) (91). Vaccines against 
influenza are available, and recommended for elderly and other risk groups. The vaccines are 
updated and adjusted according to the circulating strains of the virus, and vaccination needs 
to be repeated on a yearly basis. Influenza is mentioned as a neglected disease in febrile 
travellers and consider vaccination (92, 93). 
2.4.3 Leptospira spp. 
Leptospirosis is a zoonosis associated with exposure to soil and water contaminated by urine 
from animal carriers, mostly rodents, of the bacteria. Both domestic and wild animals can be 
affected. Research articles are mainly found on the veterinary field (94). Infected persons can 
present with mild symptoms mimicking other diseases, but the disease spectrum is wide and 
the mortality high in severe cases when icterus can develop. Outbreaks have been reported 
after flooding and storms, the majority of alerts coming from the Americas, followed by 
Western Pacific and South East Asia. Comparatively few alerts come from the African region 
(95), in spite of the fact that leptospirosis is endemic in the Sub-Saharan African region. 
Taking into account the available data on human infections, the disease can be considered a 
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neglected tropical disease in this region (94). Leptospirosis can occur among travellers, and 
have particularly been associated with adventure travels (96, 97). 
Laboratory diagnostics of Leptospirosis are cumbersome, and often only available at 
reference laboratories. Several methods are used for the diagnosis of leptospirosis. 
Microscopic agglutination test (MAT) has a high specificity, detects both IgM and IgG 
antibodies and is said to be the gold standard serological test for early diagnosis of 
leptospirosis. The high specificity of the MAT test make it a useful tool for confirming the 
leptospirosis diagnosis, but the test requires culture of Leptospira strains with the risk of 
laboratory contamination and infections. In the early phase of the disease the sensitivity and 
specificity of the ELISA IgM is high, becoming positive 1-2 days earlier than the MAT. 
Detection of bacterial DNA by PCR is an alternative early diagnostic method and can also be 
used to confirm a case (94, 98). Blood for the PCR needs to be drawn preferably before or 
very shortly after antibiotic treatment is started. Otherwise the sensitivity of the PCR is 
drastically reduced, as the Leptospira will have been cleared from the blood by the antibiotics 
given (99). 
2.4.4 Rickettsia spp. 
Rickettsiae are strict intracellular bacteria. What is generally called rickettsiosis usually refers 
to two entities, Orientia tsutsugamushi (scrub typhus) and the genus Rickettsia. The 
Rickettsia can be further divided into the spotted fever group (SFG) rickettsiae (e.g. Rickettsia 
conorii, Rickettsia rickettsii, Rickettsia africae) and the typhus group rickettsiae (Rickettsia 
prowazekii and Rickettsia typhi) (100, 101). The vectors for the SFG ricketssiae are ticks, and 
several species that were previously thought to be non-pathogenic have now been reclassified 
and associated with human infection (101). Other arthropod vectors for rickettsial infections 
include lice and fleas. Clinical symptoms associated with rickettsiosis are fever, rash and 
generally eschar (102-104). Serology is still the most common used method for diagnosis 
(104), but antigens can cross react between different rickettsiae (101). The results of indirect 
microimmunfluorescens (MicroIF), using acetone fixed bacteria, needs confirmation and 
further analysis for a more detailed specification. PCR can be performed on eschar tissue or 
blood, although very few bacteria might be present in blood during the acute phase, as has 
been noted in reports on diagnostics of for instance Rocky Mountain Spotted Fever (105). 
This could be a limiting factor in PCR diagnostics of the acute disease. However, in severe 
cases it is interesting to note the PAN real time PCR for rickettsial disease was found to be 
more sensitive than previous used PCR methods (105). As in the case of Leptospira, another 
limiting factor when using PCR is if antibiotic treatment already has been started before 
taking the samples. 
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2.5 INTERNATIONAL TRAVELLERS AND DISEASE PATTERNS 
Swedish travellers 
People living in Sweden are in general relatively well protected from the spread of infectious 
diseases. Good hygienic conditions prevail and public health is well developed. Medical 
progress and preventative measures protect the population from infections that, in other 
regions of the world, may cause large scale disasters. Travel abroad among Swedish residents 
of today is intense and frequent (106). This means that infections can be brought back home 
when travelling to the tropics (107), and patients sometimes seek care presenting symptoms 
difficult to diagnose.  
Current Swedish data on cases of imported tropical diseases is mainly provided by the 
SmiNet registry at the Public Health Agency of Sweden (108). This register contains reports 
on all cases of diseases, the so called notifiable diseases, included in the Swedish 
Communicable Diseases Act from 2004 (109). Statistical reports on aggregated data from the 
register is presented at the home page of the Public Health Agency of Sweden 
https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-
visualisering/sjukdomsstatistik/. 
One of the tropical diseases included among the notifiable diseases in Sweden is malaria, a 
vector born parasite. According to statistics, a decreasing number of malaria cases have been 
diagnosed in Sweden, with approximately 90 to 120 cases being reported annually. A sudden 
peak in the number of cases occurred during 2014, with 354 reported cases. The figures for 
2015 went down to 249 cases and decreased further during 2016 to 154 reported cases. The 
years with comparatively high numbers in reported malaria cases, especially during 2014, 
corresponds in time to the influx of refugees and migrants from malaria-endemic countries. 
For dengue fever the number of cases have increased constantly over the last 10 year period, 
from around 50 to 60 cases registered 10 years ago to 225 cases during 2016. This is the 
highest number of DENV infection ever reported in Sweden. The variation might correlate to 
a change in travel patterns and other factors related to increased risks of infections in endemic 
countries. It might also correlate to the level of awareness among clinicians and the 
availability of diagnostic methods. 
Other tropical diseases, like for instance chikungunya fever, are not even included in the list 
of notifiable diseases in Sweden. This means that the ability to identify trends in disease 
epidemiology followed by returning travellers or a large influx of migrant populations 
carrying the disease is limited, depending on whether or not patient samples are sent in for 
analyses to the laboratory.  
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Studies on travel related fever 
When this research project started in 2005, few prospective studies on returning travellers 
investigating fever of unknown origin had been published (110-116). Studies with regard to 
travellers returning to the Nordic countries were particularly scarce (117). Other studies done 
had been either retrospective or limited to research reviews (118-121). Some other 
prospective studies were also initiated and published at the time (122-124).  
Studies available before 2005 reported that 2-3% of the returning travellers presented at a 
health care clinic with a febrile condition (125, 126). Then studies were published indicating 
that more than 10% of the returning travellers had fever (93), and that fever often was the 
main reason for seeking medical advice (127). Furthermore, as many febrile illnesses have 
unspecific and overlapping signs and symptoms, the task of finding the correct and complete 
diagnosis was not easy (117). A substantial number, as many or more than 25% of the 
patients seeking medical advice after travel to the tropics, were left with an unspecified or 
unspecific diagnosis concerning microbial aetiology (110, 118, 122).  
Identifying microbes and correlating them to risk factors for communicable diseases, could 
benefit preventive measures and travel advice aiming at reducing exposure when travelling to 
risk environments (128, 129). 
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2.6 MOZAMBIQUE AND INFECTIOUS DISEASES 
Mozambique is a coastal country in the south eastern part of Africa. The population was 
estimated to be approximately 28 million people in 2015 (130), with an average life span of 
approximately 55.5 years and a literacy of 58.8% in the population 15 years or older (131).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Malaria and HIV/AIDS are the major causes of death in Mozambique (132). The HIV 
prevalence among adults was estimated in 2015 to be 10.5%. Approximately 1.5 million 
people are living with HIV, more than half of the infected persons now receiving 
antiretroviral treatment (133). Being a country with high prevalence of HIV, testing for HIV 
infection is often routinely performed on patients seeking acute medical attention. The 
number of notified cases of malaria and the number of deaths it causes are declining, but this 
disease still poses major public health problems. Malaria is still the most common cause of 
death, responsible for 35% of child mortality and 29% of the adult mortality, with more than 
8.3 million notified confirmed cases and approximately 15000 deaths during 2015 (134, 135). 
Figure 3. Maps of Africa and Mozambique. 
Sources: By Shosholoza (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via 
Wikimedia Commons and By CIA (CIA, The World Factbook, 2004) [Public domain], via Wikimedia Commons 
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That being said, acute febrile illnesses are frequent in Mozambique and not all of them are 
found to be caused by malaria. Also other aetiologies need to be explored.  
In recent years, CHIKV and DENV have caused several outbreaks and epidemics in the West 
Indies and the Americas, as well as in sub-Saharan Africa and Madagascar and in southern 
Europe (136-139). The importance of these pathogens has become more evident with time, as 
the burden of disease for malaria decreases in endemic areas (140). In fact a wide majority of 
the patients seeking medical attention for fever in the tropics are negative when tested for 
malaria (5). In spite of this, in Sub-Saharan Africa, including Mozambique, febrile patients 
are often assumed to have malaria and treated as such. Overlooking other diseases may lead 
to a risk of sub-optimal treatment and increased morbidity among febrile patients (6, 136, 
141). The overdiagnosis of malaria and the inadequate diagnostics are therefore a cause of 
concern.  
Further diagnostic investigations are not always done due to a lack of epidemiological data on 
alternative diagnosis to malaria in combination with poor laboratory capacity. Thus, viral 
zoonotic disease patterns among humans in low-income countries such as Mozambique have 
not yet been extensively surveyed. The number of reports published has been limited (142-
144). One of the probably overlooked and underdiagnosed causes of infections in Africa is 
DENV (136). 
A sero-epidemiological study conducted more than 30 years ago in Mozambique, found 
antibodies to RVFV in 2% of pregnant women (145). Studies on Rift Valley fever endemicity 
among cattle in the Maputo Province during 2010-2011 showed a sero-prevalence of 36.9 %, 
indicating that RVFV is prevalent among bovines (146). There has also been a movement of 
the human population from the rural areas to the major cities, particularly to the capital 
Maputo, with a large influx of residents to the suburban areas (147).The change in living 
conditions might have an impact on the spread of viruses as well as disease patterns since 
urbanization often leads to an aggregation of susceptible human hosts, frequently living under 
socioeconomic conditions promoting vector population expansion and at increased risk of 
arbovirus transmission (20).  
Further studies and reports are now being published, giving background data on the spread of 
emerging viral diseases in the human population, providing a basis for future actions of 
prevention and intervention. In March 2015 the Health Ministry in Mozambique confirmed 
an ongoing outbreak of dengue fever in the northern province of Nampula while a previous 
outbreak in 2014 in a neighbouring province was contained (148). A recently published study 
from Mozambique on CHIKV infection found seroconversion or a four-fold increase in 
antibody response against CHIKV in 4.3% of the examined febrile patients, indicating that 
CHIKV is circulating in southern Mozambique (149).  
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2.7 PUBLIC HEALTH ASPECTS 
Relevance for public health  
Surveillance and knowledge about disease patterns constitute a foundation for public health 
actions aimed at preventing diseases at the population level (150). The spread of 
communicable diseases is often multifactorial. Apart from the risk of travel, other 
determinants of health can facilitate the spread of infections and thus affect public health. 
Such determinants of health are for instance international transport and trade between 
different parts of the world, global movement of populations as well as climate and 
environmental change (4). The effects of climate change on human health have recently been 
highlighted, stating that there is both a direct risk of outbreaks resulting from extreme 
weather events, but also an indirect risk even of slighter climate changes resulting in altered 
geographical distribution of vectors (151). Furthermore, the WHO and UN Health and 
Environment Linkages Initiative (HELI) encourages countries to address health and 
environment linkages, emphasizing prevention and control, while pointing at vector borne 
diseases as one of the priority risks (152). 
The current general theory of epidemiological risk transition is linear and directed towards 
the relatively increased burden of disease caused by non-communicable diseases (153). When 
it comes to communicable diseases, one could argue that the epidemiological transition 
should not always be viewed as linear. It could be looked upon as having a certain trend due 
to public health actions, but still have the potential of regression and move back to an earlier 
stage if these actions are not sustained, spreading more widely and leading to outbreaks. 
There is indeed always a risk of reversed epidemiological transition, with re-emergence of 
infections considered to be under control (154-156).  
Keeping communicable diseases in focus as a health risk enables timely introduction of 
public health interventions in the form of relevant preventive measures, particularly in 
endemic countries. But this focus is also applicable to travellers and in migrant populations. 
Evidence based public health is important, as it leads to interventions directed towards 
exposed populations with adequate and high quality information on prevention (157). 
Identifying microbes and correlating them to risk factors for communicable diseases remains 
therefore essential, not only for appropriate surveillance and correct diagnosis of infectious 
diseases but also for decision making on public health actions. The interaction between public 
health actions and individual prevention is obvious. Both perspectives need to be 
implemented for optimal outcome. 
An example of the importance of keeping these to perspective in mind is the ZIKV outbreak 
in the Americas. This challenging situation had public health effects at a broader international 
scale, being recognized as a Public Health Emergency of International Concern in the WHO 
statement of the International Health Regulations Emergency Committee on ZIKV in 
February 2016 (158). In the initial stages of the outbreak, when many risks and risk factors 
were still unknown, public health authorities in many countries struggled with giving advice 
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and relevant recommendations due to the severe effects the disease could have on pregnant 
women and their unborn child. This was particularly true regarding worried travellers and 
pregnant mothers in despair, contemplating abortion (159). In Europe, the established 
exchange of information and synchronization of measures in accordance with EU legislation 
on cross border threats to health proved to be essential in this situation (160). The European 
Centre for Disease Prevention and Control (ECDC) played an important role in providing 
updated risk assessments as a tool for support, summing up facts, analysing risks for Europe 
and giving advice to Member States (161-163).  
 
Consequences of preventive measures not being maintained  
A significant reduction in the number of cases related to a disease not yet been completely 
eliminated, may lead to paradoxical and unexpected challenges for public health. When an 
infection is perceived to be successfully controlled and rarely occurs, the perception of the 
risks implied by the disease may also change. This could lead to a neglect or disregard of 
preventive measures. Individual and public health actions might not be thought of or be 
followed to a lower degree by the population. This lowered risk perception has for instance 
been noted when analysing insurance data and costs (164). Measles for instance is a disease 
that can easily be spread from country to country by non-immune travellers (2, 165), this fact 
should emphasize the importance of high vaccination coverage in any population against this 
disease. In spite of that, measles outbreaks still occur in Europe from time to time, mainly in 
pockets of low vaccination coverage but with the potential to spread to other areas where 
vaccination coverage is suboptimal (166-168). Other factors may also coincide and 
complicate the task of finding correct and complete preventive measures. Research findings 
show that some of the arboviral diseases, like CHIKV, seems to have a natural cycle with re-
emergence and outbreak of the disease after a period of time (169). Thus the increased 
number of CHIKV cases in Asia during the 1960-70s was followed by a period of 
stabilization and decline before re-emerging in 2005.  
Continued research will thus always be necessary to enable adequate and high quality 
preventive measures. 
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3 THE PRESENT STUDIES  
Infectious diseases associated with residence in or travel to the tropics constitute a diagnostic 
challenge. A broad spectrum of febrile illnesses with unspecific and overlapping signs and 
symptoms makes advice and diagnosis to febrile travellers and residents of tropical areas 
particularly difficult for the clinicians involved. 
The current thesis focuses on and explores the epidemiology and diagnostic possibilities in 
two contexts: Sweden and Mozambique. 
Today´s international travelling is intense (170). Many travellers come back with fever, and 
in about 30% or more of the cases the microbiological diagnosis is unknown. Residents living 
in tropical countries, such as Mozambique, are also left with unclear diagnosis and are often 
presumed to have a malaria infection, without further investigations being carried out.  
Since disease patterns and spread of infections are changing over time, it is of particular 
importance both to increase access to relevant epidemiological information and to provide 
reliable diagnostic methods that are easy to use for health care. 
Study rationale 
My research aimed at broadening the evidence base necessary for decisions on preventive 
measures and diagnostics, seeking to improve the tools for clinical investigation. 
Furthermore, the studies aimed at raising awareness of travel related tropical diseases.  
The research cooperation with our colleagues in Mozambique opened for an increased and 
shared knowledge regarding the epidemiology of vector borne diseases. It also provided an 
added value in both our countries, Sweden and Mozambique. Learning from each other’s 
experiences broadened our perspectives.  
Papers presented 
Two of the papers (I and V) are based on a Swedish multicentre study on febrile travellers 
returning from tropical areas of the world.  
For two of the presented papers (III and IV) the study material is from Mozambique and the 
work has been done in cooperation with our colleagues there.  
One paper (Paper II) describes the methodological development of a universal PCR for 
DENV. 
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4 MATERIAL AND METHODS 
DATA SOURCES AND COLLECTIONS 
Study areas and populations (Papers I, III, IV, V) 
Papers I and V 
Recruitment of adult patients with fever after travel to malaria endemic area, seeking medical 
attention at Swedish hospitals with an infectious disease department during 2005-2008. 
Informed consent was given at inclusion. The inclusion criteria were travel within two 
months prior to consultation, age 18 years or above, a documented temperature of 38C or 
higher (oral, axillary or rectal) at admission or within the last two days (as reported by the 
patient) and the clinician’s decision to perform a blood film examination for malaria. The 
catchment area covered 3.3 million inhabitants, constituting 1/3 of the whole population in 
Sweden. 
Paper III 
Febrile patients seeking medical attention at the Polana health centre, in the suburbs of 
Maputo, during 2012-2013 were included in the pilot study after informed consent. The 
catchment area was 4,663 km2, with an estimated population of 46184 inhabitants. 
Paper IV 
Febrile patients seeking medical attention at the hospitals in the cities Nampula and Pemba 
2015-2016 were included after informed consent. The recruitment area was Nampula and 
Cabo Delgado provinces in northern Mozambique, with a population of approximately 
470,000 in Nampula and 140,000 inhabitants in Pemba.  
Questionnaires (Papers I, III, IV, V) 
Epidemiological information was collected in a questionnaire at the time of inclusion. For 
Paper I and V a follow-up questionnaire 1 month or later after the first visit was filled in by 
the clinician. 
Blood samples (Papers I, II, III, IV, V) 
In the studies for Paper I, III, IV and V, blood samples were collected after informed consent. 
The samples were anonymised and then analysed within the research project.  
For Paper II serum samples from the biobank at the Public Health Agency were used in 
accordance with the assignment of the national authority – see 5.6 Ethical considerations.  
LABORATORY METHODS 
The laboratory methods used have been described in the background chapter of the 
introduction and are referred to in the results and discussion for the individual papers.  
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5 RESULTS AND DISCUSSION 
5.1 PAPER I 
Serologic Analysis of Returned Travelers with Fever, Sweden 
The first paper is about Swedish travellers coming home from different tropical areas of the 
world. In this multi-centre study patients were enrolled at five of the Swedish hospitals with 
an infectious disease department. The paper describes epidemiological data and presents 
results from screening for antibody response against presumed pathogens in this group of 
patients.  
During the period 2005-2008, 514 patients fulfilling the inclusion criteria were prospectively 
included after giving an informed consent. The material to be analysed included 
questionnaires and blood samples. For 383 patients we obtained a paired blood sample of 
acute serum and a follow up convalescent sample. For these patients with paired blood 
samples we choose to look for the most probable causes of fever and using the methods 
available at the time – that is approximately 10 years ago.  
In the article we included two sets of patients. The multicentre study with prospective case 
finding included 514 patients, of whom 383/514 provided a paired sera. A retrospective case 
finding group of 918 patients was also included, based on a malaria test having been 
performed in the individual case. The analysis of the retrospective control group confirmed 
the representativeness of the material included in the prospective study. 
The study analysis in the prospective group was based on the epidemiological analysis of the 
questionnaires, including the clinician’s assessments of diagnoses, and results of antibody 
screening of the serum samples. Serology for influenza A and B were performed at the 
Department of Microbiology Malmö University Hospital. MAT and PCR for leptospirosis 
were undertaken at Statens Serum Institute (SSI) in Copenhagen, Denmark in order to 
confirm the positive findings at SMI for Leptospirosis. All other analyses were performed at 
the Swedish Institute for Infectious Disease Control (SMI). The pathogens in focus, for which 
all 383 convalescent samples were screened, were: Influenza A and B viruses, DENV, 
CHIKV, Brucella spp., Leptospira spp., Coxiella burnetii, Rickettsia spp. (Typhus group: 
R.typhi, R.prowazekii; and Spotted fever group: R. africae, R.conorii). When the travel 
destination was to Asia, serology for Orientia tsutsugamushi and Japanese encephalitis virus 
was added. 
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When analysing the questionnaires we found that the most common reported dismissal 
diagnoses reported by the clinicians for the 383 patients were “unknown fever” (30%), 
followed by gastroenteritis (24%), malaria (7.5%), pneumonia (5%) and septicaemia (5%). 
Influenza was diagnosed in 2% of the cases. The additional study serology found antibody 
response against a number of pathogens, adding an infectious disease diagnosis to cases that 
had been missed to diagnose in the clinical setting (see table 2). Particularly the number of 
influenza cases increased. After the additional serology, infection with influenza was the 
specified diagnosis most frequently found, with 9 % (34/383). Among the influenza cases, 
25% had occurred outside the usual time frame for the northern hemisphere influenza season. 
A majority of these latter patients had returned from a trip to Africa.  
Overall the study serology reduced the number of cases with fever of unknown origin from 
115 to 91/383, a reduction of 21%. Positive findings also added a diagnosis of infectious 
disease illness (co-infection) to 23/283 patients already diagnosed with one infection. DENV 
co-infection was for instance found among cases already diagnosed with Salmonella 
gastroenteritis, Borrelia infection, or pharyngitis. Co-infection with influenza was found for 
pyelonephritis, salmonella sepsis, giardiasis, malaria falciparum parasitemia, pyelonephritis 
and erysipelas. A leptospirosis case was combined with pyelonephritis and rickettsiosis with 
malaria (P. malariae). 
Table 2. Summary of results for the prospectively included febrile travellers 
Analysis of 383 
febrile travellers 
returning from 
the tropics 
Microbiological 
diagnosis given 
by the clinicians 
Extended serology adding 
diagnosis 
Total number 
diagnosed 
including  
additional 
serology 
 
n=383 
Adding a 
diagnosis to the 
cases with fever of 
unknown origin 
n=115 / 383 (30%) 
Co-infection 
Disease  patients 
diagnosed 
patients 
diagnosed 
patients  
(% of 383) 
Influenza 8 12 14 34 (9 %) 
DENV fever 11 3 3 17 (4 %) 
Rickettsios 7 6 4 17 (4 %) 
Leptospirios 1 2 1 4 (1 %) 
Q fever 2 1  3 (0.7 %) 
CHIKV fever   1 1 
Fever of unknown aetiology still after 
additional serology 
91 (24 % of 383)   
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When summing up the data, we came to the conclusion that influenza was a frequent cause of 
fever among travellers returning from the tropics, regardless of the time of the year the travel 
had taken place. Other studies confirm that influenza is frequent among travellers (171) .We 
found that this infection was often missed in routine diagnostics of febrile travellers. The 
extended laboratory analysis also indicated rickettsia, dengue virus and leptospira as 
alternative infections to be considered. 
Interestingly, 24% of the patients were still left with an unknown aetiology to their fevers. 
Further research to bring knowledge on the epidemiology and spectrum of diseases brought 
to Sweden by travellers returning from the tropics could be of relevance. 
The advantage of the study is that it is prospective, allowing for the collection of blood 
samples and patient questionnaires. However, since the epidemiological part of the study is 
purely observational no analysis on for instance interventions can be done. Neither do we 
have a denominator to calculate prevalence in the overall group of travellers to the tropical 
destinations of interest. A confounding factor to the results received could be that some of the 
febrile illnesses may not be related to the travel abroad, but to exposure that could have taken 
place after the return home. It would have indeed been interesting to make a similar study on 
travellers already identifying them prior to their trip, and then upon arrival back home 
dividing them in control group and clinical cases depending on their clinical status. 
Performing such a study was unfortunately not feasible within this project, considering the 
time and resources available at the time. 
 
5.2 PAPER II 
Universal Single-Probe RT-PCR Assay for Diagnosis of Dengue Virus Infections 
In the second paper we describe the development of a new universal one step real time-PCR 
for diagnostics of dengue virus infections regardless of serotype (1-4). The real time PCR 
assay has been designed on the basis of all complete genome sequences (n=3305) of the four 
DENV serotypes published so far. 
DENV is often considered the most important arboviruses worldwide. It is probably causing 
about 50–100 million infections per year and poses a threat to 2.5 billion people in tropical 
and subtropical regions. The risk for travellers is obvious. To diagnose travellers returning 
from different parts of the world can be a diagnostic challenge. Reliable and easy to use 
methods for diagnosing DENV during the early acute phase of infection are of great value, no 
matter which part of the world the traveller has visited. The methods should be possible to 
use both in endemic parts of the world and in the home-countries of returning travellers.  
The test options for early detection of acute dengue infection are for instance NS 1 antigen, 
serology (IgM) and PCR.  
To target all variants of DENV strains by PCR would be an advantage. This would then mean 
targeting the genome of all dengue virus serotypes 1- 4 simultaneously, including new and 
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old strains as well as spill over sylvatic DENV strains to humans, in a single probe PCR 
assay. To achieve this all the complete genome sequences of dengue virus serotypes 1, 2, 3, 
and 4 published in GenBank November 2013 (n= 3 305) were analysed. In this process we 
used the tool BLAST, Basic Local Alignment Search Tool, searching for regions of similarity 
between sequences. We found one large enough and highly conserved region (64 
nucleotides), and this region is the target for the primers and probe. The universal PCR has 
been tested and evaluated in different ways. An example being the analysis of 60 saved acute 
blood samples from patients with known DENV infection (see Fig 4 page 7 in Paper II). The 
different patients had been having symptoms for a different number of days, ranging from 1 
day to 9 days, when the blood samples were collected. The viral load in the samples in 
relation to how many days the patients had had symptoms is displayed. The results show a 
high sensitivity of the universal PCR method, detecting 100% of the cases during the first 5 
days post onset of disease. On day 9, with only a low number of genome copy equivalent still 
present, more than 50% of the cases are found PCR positive. The high sensitivity for the 
universal DENV RT-PCR was again noted in 23/23 PCR positive samples among which only 
20 were positive by the NS1 antigen test, while these three positive results were confirmed by 
the CDC DENV-1-4 RT-PCR Assay. 
The universal RT-PCR method was found to have a high sensitivity and specificity for early 
detection of dengue virus infection, and allows to detect diverse strains of the virus. It is thus 
a quick and efficient way to diagnose all serotypes of dengue 1-4. To assure a continued 
accuracy the sequences need to be checked on a regular basis against the Gen Bank at NCBI 
(National Center for Biotechnology Information, U.S. government-funded national resource 
for molecular biology information). The method is based on a highly conserved region, and 
the continuous sequence update shows that it still takes everything in the database. 
The main added value provided by the method is that it allows to detect diverse strains of the 
virus. In the article we suggest that this universal PCR should be used as a first choice 
diagnostic method as an alternative to NS1 during the first 5 days of symptoms consistent 
with dengue virus infection.  
5.3 PAPER III 
Sero-epidemiologic Screening for Zoonotic Viral Infections, Maputo, Mozambique 
The third paper presents results from a pilot sero-epidemiologic screening for zoonotic viral 
infections (CHIKV, DENV, Hantavirus, RVFV and WNV) in Maputo, Mozambique.  
Only limited epidemiologic data on alternative diagnoses to malaria is available in Sub-
Saharan low-income countries. In these setting, urbanization and social factors as well as 
international trade could affect particularly the epidemiology of vector borne diseases. For 
Mozambique no such data was available. We were eager to start investigating it, and choose 
to focus on zoonotic viral infections. 
In this pilot study febrile patients were prospectively included (N=78) during 2012-2013. 
Paired acute and convalescent blood samples were collected and screened for IgG and IgM 
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response to zoonotic viruses. Results for the 23 patients with positive responses are shown in 
the table below. Real- time RT-PCR was performed on all 78 samples, investigating four 
pathogens (CHIKV, WNV, RVFV and DENV). All of the PCRs were negative. 
Among these Maputo residents 23 of the 78 patients (29.5%) had a positive serology for one 
or more screened viral pathogens, indicating previous exposure to these viruses. Ig G against 
CHIKV is clearly the most prominent finding in this pilot study, with 19% positive samples. 
Two of the 10 DENV positive patients had a positive IgM test against DENV, indicating a 
current acute infection with DENV. 
The positive IgG against WNV might be the response of cross reactivity within the flavivirus 
complex, since in two patients it was found together with positive IgGs for DENV and 
CHIKV, with the lower IgG titer against WNV. Cross reaction with antibodies against yellow 
fever vaccination is also a possibility. 
One patient was positive in the IgG screening for RVFV. Further investigations and wider 
testing regarding RVFV might be warranted, when considering that an investigation in the 
late 1980s found antibodies against RVFV in 2% of pregnant women in Mozambique (145). 
Additionally a study in the Maputo province in 2010-2011 showed a sero-prevalence of 37% 
among cattle (146). These findings in combination with the results of this pilot study could be 
an indication of a potentially emerging RVFV infection among humans in Mozambique. 
 
 
 
 
 
 
 
 
 
     Figure 4. Positive findings in the screening for IgG and IgM response to zoonotic viruses 
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Table 3. Summary of positive results for screening against viral antibodies and 
microscopy for malaria parasites 
Organism Positive screening results  
Maputo residents  n= 78 
               %  n 
CHIKV  19.2 % 15 
DENV  12.8 % 10 
RVFV    1.2 %   1 
WNV    3.8 %   3 
Malaria parasites  19.2 % 15 
Total positive serology 
against viral pathogen 
 29.5 % 23 
 
 
A screening for malaria parasites was performed on all 78 included patients and 15 (19.2%) 
malaria positive patients were found. Three of the 15 malaria-positive patients had a positive 
serologic finding (2 for DENV IgG and 1 for CHIKV IgG). 
This investigation shows that 29.5% of the included patients had a positive serological 
finding for one or more of the viral pathogens studied, an indication of previous exposure. 
The IgG results show that chikungunya virus, dengue virus and Rift Valley fever virus are 
circulating in Mozambique. These pathogens have therefore to be considered as differential 
diagnosis in febrile patients in the Maputo region. The main finding was IgG antibodies 
against chikungunya virus detected among 19% of the tested individuals. Another publication 
confirms the presence of CHIKV in Mozambique showing seroconversion or a four-fold titer 
increase in 4,3% of febrile patients (149). The positive Ig G result for CHIKV have recently 
been confirmed by NT test (personal communication with Eduardo Samo Gudo).  
For RVFV a high prevalence among cattle in the Maputo region has been shown in 2010-
2011, and it would be of interest to further explore the risk of exposure for humans. 
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5.4 PAPER IV 
Dengue virus serotype 2 established in northern Mozambique (2015-2016) 
Paper IV is a study on the ongoing outbreak of DENV infection in northern Mozambique. A 
previous DENV outbreak had taken place in Pemba 1984 to1985, and was also the first 
documented DENV-3 in Africa (142) The current outbreak started in 2014, again in the 
northern parts of Mozambique, involving the cities Pemba and Nampula (172). The aim of 
the study was to confirm the DENV serotype and to follow the trend of the outbreak. For 192 
of the 290 patients initially recruited, a rapid test for non-structural protein 1 (NS1) antigen 
was available and performed at the hospital emergency unit. Blood samples from these 192 
patients were then sent to the national laboratory in Maputo for further analysis. NS 1 was 
positive in 60 (31%) of the 192 tested patients and DENV IgM antibodies were found in 
39/192 (20%). The CDC DENV-RT-PCR was then performed on 23 of the NS1 and/or IgM 
positive samples. The result showed 21/23 PCR positive, all for DENV-2 serotype. For three 
of the DENV-2 strains a sequence analysis was performed, showing genotype Cosmopolitan, 
the same strain that had previously been described from an outbreak in Tanzania, close to the 
northern border of Mozambique (173). An epidemic curve for the Mozambique outbreak 
showed that the highest incidence of DENV infection was seen between February and May, a 
period of heavy rainfall in Mozambique. With DENV-2 now established in Mozambique, the 
risk of resurgence and spread of the outbreak within rainy seasons is evident. 
5.5 PAPER V 
Unknown fever among travellers to the tropics- possibilities for early detection with PCR 
In Paper V we analysed the material collected in the Swedish prospective multicentre study 
on tropical fever earlier described in Paper I, but with a different angle compared to the this 
publication. The primary aim now being to evaluate possibilities for early diagnosis with 
PCR, particularly in regard to patients with unknown fever. We thus analysed the acute 
samples with PCR. This differs from Paper I, where the focus was on serology, with a 
screening performed primarily on the convalescent serum samples, and in the event of 
positive titers further investigated by paired serum samples (acute and convalescent).  
For this part of the study we identified 175 patients among the 415 totally included in the 
prospective study. These 175 subjects were selected on the basis of the following criteria:  
- Patients from whom blood samples (serum and/or EDTA blood) only were available from 
the time of inclusion without a follow-up convalescent sera. These patients had not been 
included in the analysis performed for Paper I.   
- Patients without a verified microbiological diagnosis, thus having tested negative in the 
serologic analysis of Paper I. 
- To be eligible for PCR testing, the blood sample should have been collected within the first 
five days of disease.  
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The patient samples were analysed with PCR for the following arboviruses and bacteria: 
DENV, CHIKV, ZIKV, Leptospira spp., Rickettsia spp. The reason for not only studying 
arboviruses but also adding Leptospira spp. and Rickettsia spp. was our previous finding of 
additional Leptospira and Rickettsia cases in the serology study, making us interested in 
knowing if it would be possible to find even more cases with PCR:  
From the originally include 175 patient samples, two were excluded from viral RNA analysis 
due to a negative internal control test for Beta-actin. In the remaining 173 samples we found 
that seven patients (4%) were DENV PCR positive. Four of those seven had not previously 
been tested for DENV infection, and could be considered as overlooked in the clinical 
diagnostic procedure. In the other three cases, the clinician had tested and found a positive 
IgM result for DENV in the acute sample. In spite of already having a probable diagnosis, 
neither a confirmation follow-up serum nor a previous negative serum sample showing 
seroconversion had been taken. In these three cases the new finding of a positive PCR for 
DENV confirmed the diagnosis (174). Serotyping with PCR was done for all seven PCR 
DENV positive cases, showing two cases of DENV-1, one case of DENV-2 and two cases of 
DENV-3. DENV serotyping with PCR was negative for two of the seven cases, which could 
be explained by the lower threshold for detection of the single probe universal RT-PCR used 
for DENV diagnostics in comparison to the in general higher threshold for the individual 
PCRs performed for serotyping DENV. Epidemiological data from the questionnaires 
showed that the DENV positive cases had visited Asia and South America, but not Africa. 
The DENV negative travellers had to a greater extent been to Africa. However, since there 
were only 7 individuals in the DENV positive group, it is difficult to draw any general 
conclusion regarding risk for exposure and destination of travel from those results.  
PCR for CHIKV and ZIKV were all negative, corresponding to the material having been 
collected during 2005-2008, before these viruses had become more widely distributed in the 
tropical world. The spread of CHIKV started to escalate in 2006 with the outbreak on the 
islands in the Indian Ocean (175, 176). Regarding ZIKV, until 2007 it had only been found in 
Asia and Africa, when a local outbreak occurred in Micronesia without any recognised 
further spread until 2013 (61, 177).  
The PCRs for Rickettsia and for Leptospira were all negative in the 172 patient samples 
included in this part of the study. Furthermore, when analysing 13 previously diagnosed cases 
of rickettsiosis, verified by paired serology and published in Paper 1, they were also negative 
in the PCR. Other studies screening febrile patients with PCR for rickettsia have also shown a 
negative result (178). Similar to our group of patients, they also had mild symptoms. The 
universal PCR method for rickettsia that our method is built on has been shown to be more 
sensitive than previous used PCR methods, and being able to detect rickettsial DNA in severe 
cases (105). Patients with rickettsiosis may have very few organisms present in blood during 
the acute phase, which limits the possibilities for genome detection. The presence of 
antibiotics diminishing the number of or eradicating the bacteria from the bloodstream can 
also explain the negative PCR result. Unfortunately, information about antibiotic treatment 
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given prior to sampling blood for the PCR analysis was not available. A review on 
Rickettsiosis noted that there were several new species identified as pathogens (101), which 
also could explain differences in serology and PCR results. This means that early laboratory 
verification of a rickettsial disease remains a challenge. A negative PCR does not exclude 
disease, while a positive PCR might indicate the need for prompt treatment. During this early 
phase the decision on antibiotic treatment thus still depend on the clinical suspicion of 
rickettsial disease (179). Serology, with an acute and a follow-up paired serum sample, could 
then be used to confirm the suspected diagnosis in a PCR negative patient.  
When performing the PCRs for viral RNA we used Beta-actin as an internal control to verify 
the extraction procedure and the presence of RNA in the samples. Despite all samples having 
been handled and stored in the same way, 10 of the initial 175 patient serum samples were 
negative for Beta-actin. Furthermore, when the corresponding plasma for these 10 samples 
were tested, 8 of 10 became PCR positive for Beta-actin. All the samples had been collected 
during 2005-2008 and stored at -20C. That means about 10 years of storage prior to the PCR 
procedures. RNases can degrade RNA samples, giving a negative PCR results. It might be 
that in some samples the RNA had degraded during the storage period. Other risks are 
inhibition, leading to a false negative result (180). In fact, no obvious explanation for the 
differences between plasma and serum has been identified neither when searching the Pub 
Med database nor when discussing with the helpdesk at the manufacturer of the extraction 
kits (181-184). According to the manufacturer (personal communication August 2017) the 
extraction method has been evaluated for plasma. The question is if RNA is more stable when 
stored in plasma rather than in serum for a long period of time. The question is also if Beta-
actin as house-keeping gene varies in expression or is prone to degrade (185-187). 
5.6 ETHICAL CONSIDERATIONS 
Ethical approval for the Swedish multicentre study (Papers I and V) was given by the 
Regional Ethics Committee (Stockholm). The two studies performed in Mozambique (Papers 
III and IV) were approved by the National Bioethical Committee in Mozambique (Ministério 
da Saúde, Mozambique, comité nacional de bioética), with a corresponding approval from the 
Swedish Regional Ethics Committee (Stockholm) for the procedures in Sweden. Written 
consent was obtained from all the participants in the Swedish multicentre study (Papers I and 
V), and for the two studies where patients were included in Mozambique (Papers III and IV).  
Paper II is a methodological development performed at the Public Health Agency of Sweden. 
The Department of Microbiology at the Agency is a reference laboratory and a Swedish 
referral laboratory for a number of pathogens causing infectious diseases originating from for 
instance tropical areas of the world. Methodological development is within the national 
authority’s mission being stated and commissioned by the Government in the Regulation SFS 
2013:1020, 3§, points 2 and 8 (https://www.riksdagen.se/sv/dokument-lagar/dokument/ 
svensk-forfattningssamling/forordning-20131020-med-instruktion-for_sfs-2013-1020). While 
not requiring ethical permit nor written consent, in accordance with the allowance for the 
Public Health Agency of Sweden to use samples from the biobank of the Public Health 
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Agency of Sweden (former Swedish Institute for Infectious Disease Control, SMI) for such 
development and quality control relevant for the authority’s mission, it goes without saying 
that both the researcher and the project leader are required to put ethical considerations high 
on the agenda. Routines, rules and regulation applying to laboratory work at the Public 
Health Agency of Sweden are to be strictly followed, including those relating to data 
protection.  
In our studies, personal identifiers were anonymized at the including clinics before sending 
blood samples and questionnaires to be analysed. The key to personal data files was kept at 
the including centres. Similar regulations for sample collection and analysis also apply in 
Mozambique.  
When it comes to positive research findings and potential impact on patient care, HIV was 
considered to be ethically disputable to include in the research panel of Study I and V where 
patients in Sweden were included. Decisions on testing for HIV were left for the clinicians to 
make in direct contact with the patients involved. In Study III and IV concerning patients in 
Maputo, where the endemicity for HIV is comparatively high, HIV testing as well as testing 
for malaria was routinely done by the clinicians on admission for fever. Thus the clinical 
routine testing differs between the two settings (Sweden-Mozambique). 
All five papers are examples of the interaction between the individual patient perspective and 
the public health aspects. On one hand, our research focuses on individual patients when 
investigating the panorama of infections among febrile returning travellers or suburban 
population in Maputo. The aim is to contribute to a more correct diagnoses, better diagnostic 
tools and improved individual advice on preventive measures. On the other hand, we also 
wish to contribute the public health aspects on the national level, providing a basis for a 
broader preparedness against infections in Sweden or Mozambique. The results of these type 
of studies could contribute to decision making, while taking into account the importance of 
ethical considerations in the steps involving individual patients.  
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6 CONCLUDING REMARKS 
REFLECTIONS AND PERSPECTIVES FOR THE FUTURE 
The study approach in Paper I, III, IV, V is prospective descriptive. There are some 
differences between the studies, for instance in regard to age, gender and results of screening 
for malaria between Swedish travellers and Maputo residents with fever (see table 4). The 
risk for malaria is clearly higher for Maputo residents with 19% positive cases compared to 
the 7.5% malaria positive patients in the group of Swedish travellers. The difference in 
median age might on the other only reflect the difference in median age for the population as 
a whole. More women than men were included in the Maputo study. The opposite was seen 
in the Swedish study. It is interesting to note the differences in gender, but the limited 
information available makes it only possible to speculate on the factors behind the data and 
whether sampling effect or individual patient factors play a role.  
 
Table 4. Swedish travellers and Maputo residents 
 Paper I 
Sweden (travellers) 
Paper III 
Maputo (residents) 
Number of patients 383  78  
Median age in years 
(age span) 
37  (18-76) 29 (5-78) 
Female gender 42   %  162/383 59 %  46/78 
Malaria positive  7.5 %  29/383 19 % 15/78 
 
 
Both travellers and residents in tropical countries face the risk of exposure to the infections 
we have studied in this thesis. When infected, the diseases will often present with unspecific 
symptoms. The individual risk of exposure can differ depending on factors not only 
associated with where in the tropics the person has been, but also such factors as type of 
housing, outdoor activities and risks taken. With communicable diseases emerging and re-
emerging, increased travelling does not necessarily have to lead to an increased risk of 
exposure in general. Human interaction and exchange of knowledge and science, where all 
can contribute with different perspectives, is the source of better ideas for prevention. In this 
respect, both epidemiology and laboratory diagnostics can bring evidence to allow for better 
decisions on public health measures for both travellers and residents in tropical countries. 
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The diagnostic challenges related to unspecific symptoms and broad spectrum of diseases are 
common both regarding travellers and residents of tropical areas. On one hand we would 
wish for quick and easy ways to perform diagnostic tests with high sensitivity and specificity, 
if possible covering multiple diagnoses. On the other hand, in the perspective of travel and 
particularly to the tropics, adequate individual pre-travel advice and other preventive 
measures including relevant vaccinations should not to be forgotten. 
Today, wrapping up the thesis, I would have liked to include a more recent follow-up study 
for the Swedish multicentre study on returning travellers. It would be very interesting to 
perform a PCR screening on acute samples for arboviruses, for instance including DENV, 
CHIKV, ZIK and maybe WNV. I would then have added sampling of nasopharyngeal 
secretion from the patients, to be able to perform a rapid test or PCR for influenza on this 
material (188, 189), PCR on serum samples not being a diagnostic choice for influenza. I 
would also consider the possibility of including HIV testing in the study analysis, taking into 
account the ethical implications of such a procedure. 
Further arbovirus studies in Mozambique are needed, including a more in-depth analysis on 
the risk of human exposure to RVFV. Additionally, looking at influenza performing an all 
year round study with PCR on nasopharyngeal secretion could also be valuable.  
 
IMPLICATION FOR POLICY; PRACTICE AND RESEARCH  
This thesis wishes to contribute to the knowledge of the spectrum of infectious diseases 
brought to Sweden from the tropics by returning travellers. An extended analysis of blood 
samples from clinical cases with unknown or unspecified infectious aetiology has been made. 
This has been combined with a study of the viral zoonotic disease panorama among residents 
in a country in the tropics, namely Mozambique.  
The knowledge obtained strengthens and adds to the information on which the current 
policies on diagnostics and prevention is based. The thesis concludes that additional 
laboratory screening with serology and PCR apart from routine clinical diagnostics can 
increase the number of cases with a verified microbial diagnosis. It could be emphasized not 
to neglect the following diagnoses: influenza virus infection (regardless of the time of year), 
dengue virus infection, leptospirosis and rickettsiosis.  
While realizing the limitations of currently used laboratory methods for early detection of 
pathogens in endemic countries as well as among returning travellers, the thesis also points at 
the need for further development and research in this field. 
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LEARNING OUTCOMES 
The most important learning outcome is for me not only the mere knowledge, but the insights 
and new ways of thinking I have reached through these studies. My critical thinking has been 
nourished and nurtured in meetings with teachers, fellow students of different ages and 
experiences and colleagues from other parts of the world. Bonding between our scientific 
fields through our common human interest gives me hope for the future of science. 
The studies have provided me with an increased capacity to identify and formulate relevant 
research questions, both critically, independently and with scientific accuracy. My capacity to 
evaluate the work of others has also improved. Understanding the theoretical background and 
practical performance of molecular and immunological analysis necessary for the studies in 
the thesis was amazing. Achieving an increased awareness of strengths and weaknesses in 
different methods was also stimulating.  
I am very grateful for having made this scientific journey. In times when facts without solid 
evidence sometimes become the generally accepted truth, understanding and searching for the 
evidence behind the facts is more than ever needed. The PhD education has been a real 
source of inspiration. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Fler och fler resenärer återkommer från långväga resor, många har varit i tropiska länder och 
kommer hem med feber. Denna avhandling handlar om infektionssjukdomar med tropiskt 
ursprung. Två olika aspekter har studerats, dels effekten på invånare i ett tropiskt land, dels 
hur det ser ut bland hemvändande svenska resenärer som besökt tropiska länder.  
I den svenska studien kunde vi konstatera att influensa är en betydligt vanligare orsak till 
feber efter resa än vad tidigare varit känt, hela 9% av feberfallen. Bland tropikresenärerna 
förekom fall av influensa oberoende av årstid, dvs. även utanför det vi vanligen kallar 
influensasäsong. Malaria är förvisso en viktig tropisk orsak till feber. I studien fokuserade vi 
dock framförallt på andra orsaker till feber än malaria, särskilt på sådana som inte fångats upp 
av vården vid sedvanliga utredningar. Vid en fördjupad analys fann vi bl.a. flera fall av 
infektioner orsakade av denguevirus, som också sprids via myggor i tropiska länder. 
Sammanlagt hade 4% av resenärerna en säkerställd infektion med denguevirus. Vi provade 
även att utröna om det gick att hitta ytterligare fall med hjälp av PCR, en nyare diagnosmetod 
som vi vidareutvecklat i syfte att täcka alla hittills kända varianter av denguevirus i världen. 
Det vi åstadkommit är en enkel och snabb undersökning som kan hjälpa kliniker att ställa en 
tidig diagnos av patienten. Förutsättningen är att ett blodprov tas inom fem dagar från 
insjuknandet. Med den metoden identifierades 7 fall i en grupp om 173 patienter med oklar 
feber efter tropikresa. 
Mozambique är ett land där det fram tills nyligen endast har funnits ett fåtal vetenskapliga 
studier som beskriver läget rörande sjukdomar som t.ex. kan överföras med olika insekter. Vi 
genomförde två studier. I den ena undersökte vi patienter i en förort till Maputo. Resultaten 
visade att 19 % av patienterna hade haft en infektion med det myggburna viruset 
chikungunya. Ett antal av de undersökta patienterna, 13 %, hade antikroppar mot dengue-
virusinfektion. I den andra studien tittade vi närmare på ett pågående utbrott av denguefeber i 
norra Mozambique. Vi konstaterade att dengue-virusinfektion av undergruppen serotyp 2 nu 
är etablerad i Mozambique. Det rör sig inte längre om enstaka fall utan om en sedan 2014 
pågående förekomst. Undersökningarna i Mozambique gjordes i samarbete med lokala 
forskare och ansvariga på nationella myndigheter. Resultaten kan förhoppningsvis bidra till 
en ökad förståelse för sjukdomspanoramat i Mozambique och ingå i ställningstaganden till 
förebyggande åtgärder. 
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